A case of an asymptomatic idiopathic inhibitor to coagulation factor V

Lucía, J. F.; Aguilar, Carolina

doi:10.1111/j.1365-2516.2004.01059.x

Cited by 13 publications

(9 citation statements)

References 20 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median peak inhibitor titer was 19 BU (range 0.5-1500 BU), while the median FV activity level was 1% (range [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. While the inhibitor titer did not correlate with the level of FV deficiency nor with the bleeding risk (the median inhibitor titer in both bleeders and nonbleeders was 19 BU), a positive correlation was observed between residual FV activity and bleeding symptoms.…”

Section: Search Methodsmentioning

confidence: 97%

“…While the inhibitor titer did not correlate with the level of FV deficiency nor with the bleeding risk (the median inhibitor titer in both bleeders and nonbleeders was 19 BU), a positive correlation was observed between residual FV activity and bleeding symptoms. Nevertheless, median FV levels in bleeders were 1% (range [1][2][3][4][5][6][7][8][9][10][11][12][13][14] and 3% (range 1-20) in non bleeders (P = 0.05, Student's t-test). These results are in agreement with the recent systematic review by Ang et al [21].…”

Section: Search Methodsmentioning

confidence: 99%

“…The cases of FV autoantibodies reported in literature have been mostly associated with the presence of an associated risk factor [9], including surgical procedures, antibiotic administration (especially of the lactam group), blood transfusions, cancers and autoimmune disorders [10][11][12][13]. However, the majority of the cases previously described developed after exposure to bovine thrombin preparations, which are frequently used as topical haemostatic agents in vascular, orthopaedic and neurosurgical procedures, and often contained additional bovine proteins including FV [14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Acquired factor V inhibitors: a systematic review

Franchini

Lippi

2010

J Thromb Thrombolysis

115

211

View full text Add to dashboard Cite

The occurrence of an inhibitor against coagulation factor V (FV) is a rare but challenging condition, which may span from asymptomatic laboratory abnormalities to potentially life-threatening bleeding. The onset of FV inhibitors has been associated most frequently in the past with the patients' exposure to topical bovine thrombin administered during surgery procedures. However, since this preparation is no longer used, in this systematic review we have only focused on non-bovine thrombin-related FV inhibitor cases.

show abstract

Section: Search Methodsmentioning

confidence: 97%

Section: Search Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Acquired factor V inhibitors: a systematic review

Franchini

Lippi

2010

J Thromb Thrombolysis

115

211

View full text Add to dashboard Cite

show abstract

“…The clinical manifestations of factor V inhibitors can range from an asymptomatic laboratory abnormality, as seen in our patient, to clinically severe bleeding [1,12,13]. Even foetal bleeding due to factor V inhibitors has been reported [14].…”

Section: Discussionmentioning

confidence: 89%

Factor V inhibitor: case report

Leus

Devreese²,

Bossche³

et al. 2006

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Acquired inhibitors to coagulation factors are rare, certainly those directed against factor V. A total of around 150 cases have so far been reported, of which the greater part was due to bovine thrombin exposure. We report the case of a patient who developed a factor V inhibitor during a postoperative period. This report describes possible aetiologies, varying clinical conditions and treatment possibilities as described in the literature. Furthermore, this case report is an example of the often unpredictable disease progression in a patient with existence of a factor V inhibitor.

show abstract

“…Most cases of factor V autoantibodies reported in literature occur in the presence of an associated risk factor [33], including surgical procedures, antibiotic administration (especially of the lactam group), blood transfusions, cancers, and autoimmune disorders [34][35][36][37][38]. The majority of the cases previously described developed after exposure to bovine thrombin, and the use of this material may have also given rise to heightened rates of inhibitor development during certain historical periods according to the product used (e.g.…”

Section: Acquired Factor V Deficiencymentioning

confidence: 99%

Inherited and acquired factor V deficiency

Lippi

Favaloro

Montagnana

et al. 2011

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

The clotting factor V, also known as proaccelerin or labile factor, is synthesized by the liver and possibly by the megakaryocytes. Factor V exerts a pivotal role in hemostasis, as it participates in both procoagulant and anticoagulant pathways, being an essential cofactor of the prothrombinase complex in the former case and participating in the inactivation of factor VIII (FVIII) in the latter. Isolated factor V deficiency due to mutations in the F5 gene is a rare inherited coagulopathy typically associated with a broad spectrum of bleeding symptoms, ranging from easy bruising, delayed bleeding after haemostatic challenges such as trauma or surgery to more severe joint bleeds. The combined deficiency of factor V and FVIII, commonly known as F5F8D, is a recessive disorder not attributable to the association of isolated factor V and FVIII deficiencies, but rather to defective intracellular processing of both proteins due to mutations involving the LMAN1 and MCFD2 genes, which encode two proteins forming an essential cargo receptor complex. Overall, patients affected by F5F8D do not bleed more in terms of both frequency and severity than those carrying specific deficiencies of both factors and the bleeding phenotype is generally mild. Although now increasingly rare, inhibitors directed against factor V may also develop in individuals of any age and are characterized by a very heterogeneous clinical phenotype. The aim of the current review is to provide an overview on the physiopathology, diagnostics, and clinical management of both inherited and acquired factor V deficiency.

show abstract

A case of an asymptomatic idiopathic inhibitor to coagulation factor V

Cited by 13 publications

References 20 publications

Acquired factor V inhibitors: a systematic review

Acquired factor V inhibitors: a systematic review

Factor V inhibitor: case report

Inherited and acquired factor V deficiency

Contact Info

Product

Resources

About